MedTrace Logo

Place of the Hevylite Test in the Evaluation of MRD in Myeloma

NCT03702088 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2019-11-19

No results posted yet for this study

Summary

Study aiming at testing the positive predictive value of the Hevylite blood test in detecting minimal residual disease in myeloma compared to an invasive method requiring bone marrow sample by multi-parametric flow cytometry

Conditions

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nice

    collaborator OTHER

  • Hospices Civils de Lyon

    collaborator OTHER

  • CLB de Lyon

    collaborator UNKNOWN

  • Centre Hospitalier Universitaire de Nīmes

    collaborator OTHER

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Laure Vincent, Md · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-12-01
Completion
2020-12-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03702088 on ClinicalTrials.gov